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Functional analysis of four LDLR 5′UTR and promoter
variants in patients with familial hypercholesterolaemia
Amna Khamis1, Jutta Palmen1, Nick Lench2, Alison Taylor2, Ebele Badmus1, Sarah Leigh1
and Steve E Humphries*,1
Familial hypercholesterolaemia (FH) is an autosomal dominant inherited disease characterised by increased low-density
lipoprotein cholesterol (LDL-C) levels. The functionality of four novel variants within the LDLR 5′UTR and promoter located
at c.-13A4G, c.-101T4C, c.-121T4C and c.-215A4G was investigated using in silico and in vitro assays, and a systemic
bioinformatics analysis of all 36 reported promoter variants are presented. Bioinformatic tools predicted that all four variants
occurred in sites likely to bind transcription factors and that binding was altered by the variant allele. Luciferase assay was
performed for all the variants. Compared with wild type, the c.-101T4C and c.-121T4C variants showed signiﬁcantly lower
mean (±SD) luciferase activity (64±8 and 72±8%, all Po0.001), suggesting that these variants are causal of the FH
phenotype. No signiﬁcant effect on gene expression was seen for the c.-13A4G or c.-215A4G variants (96±15 and 100
±12%), suggesting these variants are not FH causing. Similar results were seen for the c.-101T4C and c.-121T4C variants in
lipid-depleted serum. However, a signiﬁcant reduction in luciferase activity was seen in the c.-215A4G variant in lipid-depleted
serum. Electrophoretic-mobility shift assays identiﬁed allele-speciﬁc binding of liver (hepatoma) nuclear proteins to c.-121T4C
and suggestive differential binding to c.-101T4C but no binding to c.-215A4G. These data highlight the importance of in vitro
testing of reported LDLR promoter variants to establish their role in FH. The functional assays performed suggest that the
c.-101T4C and c.-121T4C variants are pathogenic, whereas c.-13A4G variant is benign, and the status of c.-215A4G
remains unclear.
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INTRODUCTION
Familial hypercholesterolaemia (FH) is an autosomal dominant
disease characterised by high levels of low-density lipoprotein choles-
terol (LDL-C)1 that leads to an increased risk of premature coronary
heart disease.1 Recent guidelines for the identiﬁcation and manage-
ment of patients with FH recommend that mutation information
should be used to test all ﬁrst-degree relatives to ﬁnd carriers and offer
them lifestyle and therapeutic interventions, such as lipid-lowering
statin treatment, to reduce their risk of early heart disease.2 To date,
variants in three genes have been implicated in FH, low-density
lipoprotein receptor (LDLR), apolipoprotein-B (APOB) and proprotein
convertase subtilisin/kexin 9 (PCSK9).3,4 LDLR variants are the most
common cause of FH, with41200 variants identiﬁed throughout the
gene (UCL LDLR variant database: https://grenada.lumc.nl/LOVD2/
UCL-Heart/home.php?select_db= LDLR).5,6 At least 36 variants have
been described in the 5′untranslated region (UTR) and promoter of
the LDLR gene (Table 1), many of which have been shown to alter the
binding of key transcription factors involved in the control of LDLR
expression, such as Sterol regulatory element-binding protein
(SREBP), speciﬁcity protein 1 (Sp1) and cAMP responsive element-
binding protein (CREB).7–9 As not all identiﬁed variants will be
causing FH, it is important that reported variants are tested for their
pathogenicity. The functionality of four variants identiﬁed in the
literature6 in patients with a diagnosis of heterozygous FH within the
LDLR 5′UTR (c.-13A4G) or promoter (c.-101T4C, c.-121T4C and
c.-215A4G) were analysed using in silico and in vitro assays. Previous
in vitro luciferase results have shown that the variant c.-120C4T had a
signiﬁcant reduction in luciferase activity compared with the wild
type.10 This variant was used as a positive control for these experi-
ments. The location of known transcription factor binding sites in the
LDLR promoter and the positions of the tested variants are shown in
Figure 1.
MATERIALS AND METHODS
Subjects
The c.-101T4C and c.-215A4G variants were identiﬁed by the NE Thames
Regional Genetics Service laboratories, Great Ormond Street Hospital (GOSH),
in patients with a clinical diagnosis of heterozygous FH according to the UK
criteria.1 The c.-13A4G and c.-121T4C variants were reported in FH patients
in the literature.11,12 Standard nomenclature was used for describing variants
(www.hgvs.org), and the locus reference genomic sequence LRG_274 for LDLR
was used.
In silico analysis
Two transcription factor prediction tools were used: MatInspector
(www.genomatrix.de) and MATCH (http://www.gene-regulation.com/pub/pro-
grams.html#match).13,14 These tools were used to identify potential transcrip-
tion factor binding sites in the region where the variants in the LDLR promoter
were found. The matrix score calculates a match between the sequence and the
matrix. The scores range from 0 to 1, with 1 indicating an exact match.
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Cloning of LDLR promoter
The c.-600 bp to c.-5 bp region of the LDLR promoter was cloned into the
pGL2-basic vector using the HindIII restriction site.8 This was used as a
template for site-directed mutagenesis using the QuikChange Lightning Site-
Directed Mutagenesis Kit (210518-5; Agilent Stratagene Technologies,
Stockport, UK). Site-directed mutagenesis was completed to create plasmids
containing the c.-13G, c.-101C, c.-121C and c.-215G alleles. All constructs were
conﬁrmed by sequencing. The plasmids were transfected into Huh7 cells, a
human hepatoma liver cell line (01042712; European collection of cell cultures
(ECACC)). The cells were grown using Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with 10% FBS, or 10% lipid-depleted serum (from GENTAUR
Europe BVBA, Aachen, Germany; FB-1090LF/100).
Transfection and luciferase assay
Transfection was prepared when a conﬂuence of 80% was reached. The pUC18
and pGL3 control were used as negative and positive controls, respectively. The
cells were transfected using Lipofectamine 2000 (Invitrogen, Paisley, UK) and
Opti-MEM serum-free medium according to the manufacturer’s instructions
and as previously described.7 Cells were lysed using Passive Lysis Buffer
(Promega, Southampton, UK) and luciferase expression was determined using
the Dual Luciferase Reporter Assay System (Promega), and measured in the
Tropix TR717 Microplate Luminometer (PE Applied Biosystems, Paisley, UK).
Luciferase activity was determined as the mean of 8–12 transfections with the
assay performed in triplicate. EMSAs were carried out, as previously described,
to determine transcription factor binding within the variant site.8
RESULTS
In silico analysis indicated that all of the variants were likely to be
within transcription factor binding sites (Supplementary Table 1).
With the exception of the predicted CREB site at c.-101T4C, none of
these have been reported to be involved in control of transcription of
Table 1 Location of all reported variants 270 bp upstream from LDLR start of translation, with reported effect on promoter activity and
homology across human and 6 primate and 6 mammalian species (variants tested in this study are shown in bold)
Variant Promoter activity (% of wt) Location Sequence homologya Reference
c.-268G4T In FH and normal 1 bp from FP1 7/8 20
c.-220_-221insA Not tested FP1 NA 21
c.-217C4T 160% Luciferase 2 bp from FP1 13/13 20
c.-215A4G 100% Luciferase 4 bp from FP1 11/12 6
c.-208A4T 100% Luciferase Between SREBP1 and FP1 12/12 15
c.-206C4T Not tested Between SREBP1 and FP1 13/13 22
c.-193_-186delinsTG Not tested SREBP1 NA 23
c.-188C4T Not tested SREBP1 13/13 23
c.-185_-183delCTT 10% Luciferase SREBP1 NA 24
c.-156C4T Not testedb SREBP2 13/13 25
c.-155_-154delinsTTCTGCAAACTCCT 11% Luciferase SREBP2 NA 15
c.-153C4T Not tested SREBP2 13/13 26
c.-152C4T 40% Luciferase SREBP2 13/13 20
c.-146C4A Not tested Between SREBP2 and SP1 13/13 27
c.-142C4T 20% Luciferase SP1 13/13 28
c.-140C4G 7% Luciferase SP1 13/13 15
c.-140C4T 6% Luciferase SP1 13/13 15
c.-139C4A Not tested SP1 13/13 23
c.-139C4G 26% Luciferase SP1 13/13 8
c.-138delT 24% LDLR activity SP1 12/13 29
c.-138T4C 25% Luciferase SP1 12/13 30
c.-137C4T Not testedc SP1 13/13 31
c.-136C4G 12% Luciferase SP1 13/13 15
c.-136C4T 5% CAT assay SP1 13/13 32
c.-135C4G Not testedd SP1 13/13 31
c.-121T4C 72% Luciferase Between TATA box and SP1 13/13 12
c.-120C4T 3% Luciferase Between TATA box and SP1 13/13 26
c.-101T4C 64% Luciferase TATA BOX 12/12 6
c.-88G4A 100% Luciferase 5′UTR 12/12 15
c.-68A4C Not tested 5′UTR 5/11 33
c.-36T4G 100% Luciferase 5′UTR 6/10 15
c.-23A4C Not tested 5′UTR 7/12 34
c.-22delC Not tested 5′UTR 10/12 35
c.-14C4A Not tested 5′UTR 9/12 27
c.-13A4G 100% Luciferase 5′UTR 8/13 11
c.-5C4T Not tested 5′UTR 7/11 23
Abbreviations: FP1, Foot Print 1; SREBP1, sterol regulating element-binding protein 1; SP1, Speciﬁcty Protein 1.
Where the base for the sequence was not present in a particular species, the species was discounted from the total.
The NG_009060.1 reference sequence was used.
aLDLR promoter sequence conservation between Human, Pan troglodytes, Gorilla gorilla, Pongo abelii, Macaca mulatta, Callithrix jacchus, Oryctolagus cuniculus, Mus musculus, Rattus norvegicus,
Bos taurus, Sus scrofa, Canis lupus familiaris and Equus caballus (http://www.ensembl.org/Homo_sapiens/Gene/Compara_Alignments?align=609&db= core&g=ENSG00000130164&r=19%
3A11200057-11244506&t=ENST00000252444).
bCosegregation with FH reported.
c5–15% LDLR activity (when compound heterozygote with c.1222G4A, p.(Glu408Lys)).
d5–15% LDLR activity in homozygote.
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the LDLR gene. The minor differences in predicted scores for the
variants at the c.-121 site are unlikely to be of biological signiﬁcance.
For three of the variants (c.-13A4G, c.-101T4C and c.-215A4G),
one or both of the programmes used predicted that binding was likely
to be signiﬁcantly modiﬁed by the presence of the variant allele, for
example, the predicted binding of CREB to c.-101T but not c.-101C,
and the binding of HIFIA to c.-101C and not c.-101T. However,
although the c.-13G allele showed the abolition of two transcription
factors, this binding was not veriﬁed in MATCH. Moreover, in
MatInspector, the c.-120C4T variant showed an abolition of OCT1
binding site, indicating a biological signiﬁcance. However, this result
was not seen in the MATCH results.
Luciferase assays were performed to investigate the LDLR expression
in the promoter sequences containing the variant alleles compared
with the wild type. These assays were repeated in multiples of 8–12 for
each variant and are presented as the average of three independent
runs. Compared with the wild type, the c.-13G and c.-215G alleles
showed a (mean±SD) 96±15 and 100%±12% level of luciferase
activity, indicating that this variant is unlikely to be FH causing. The
c.-101T4C and c.-121T4C variants showed a 64±8 and 72±8%
lower luciferase activity compared with the wild type (all Po0.001;
Figure 2a), indicating that all these variants are likely to be FH causing.
The c.-120C4T variant was then used as a positive control, showing
83% expression as compared with the wild type (P= 0.001). All
transfection assays were repeated using cells grown in 10% lipid-
depleted serum in order to induce LDLR promoter expression.8 This
resulted in a 2.5-fold higher expression of the wild-type construct,
with similar increases seen for all variants (data not shown). However,
as shown in Figure 2b, compared with the wild-type construct, the
pattern of expression seen was similar, with the c.-13G allele showing a
96±22% level of luciferase activity, indicating that this variant is
unlikely to be FH causing, whereas c.-101T4C and c.-121T4C
variants showed 48±8 and 49±6%, respectively (all Po0.001).
Remarkably, the c.-215G allele showed a similar and signiﬁcant
reduction in luciferase activity in the absence of lipid (48±10%;
Po0.001).
EMSAs were used in an attempt to identify nuclear factors binding
differentially to the c.-101T4C, c.-121T4C and c.-215A4G variants.
Extracts from a hepatocarcinoma cell line Huh7 were used, with a
probe for the SREBP as a positive control. As shown in Supplementary
Figure 1, the positive control provided a strong band shift as well as
several nonspeciﬁc bands. Neither alleles of the c.-215A4G probe
showed a speciﬁc additional band; however, the c.-121T allele showed
an additional band shift compared with the c.-121C allele.
For the c.-101 probes, both showed evidence of a speciﬁc high-
molecular-weight band, with the c.-101C allele showing an additional
faint band (indicated by an arrow in Supplementary Figure 1).
DISCUSSION
In order to correctly report to a referring clinician whether or not an
identiﬁed promoter variant is likely to be FH causing, bioinformatics
predictions may be helpful, and although evidence that the variant
affects binding of a nuclear protein by an EMSA may be suggestive, an
in-vitro assay of the effect on transcriptional strength provides the
strongest evidence. Four reported variants identiﬁed in FH patients
within the LDLR 5′UTR and promoter were investigated.6 The
c.-13A4G variant showed no difference in luciferase activity, suggest-
ing it is not FH causing, whereas c.-101C and c.-121C showed a
signiﬁcant lower expression, suggesting that these variants are likely to
be pathogenic and causal of the FH phenotype seen in these patients,
and the status of c.-215A4G remains unclear.
The bioinformatic programmes were not helpful in this instance.
Both programmes (MatInspector and MATCH) suggested that the
c.-13A4G variant destroys binding for a nuclear transcription factor
and yet this variant did not affect luciferase activity. This is in
agreement with previous studies that have shown no causal effect of
variants within the 5′UTR region.15 Both programmes used also
suggested that transcription factors would bind to the DNA sequences
and that the variants would destroy binding. This is particularly clear
for the c.-101T4C allele that is located in the TATA-box and a
previously documented CREB binding site.7 Moreover, there were
major differences between the two programmes; for example, although
MatInspector showed a high score for the binding of two transcription
factors, MATCH did not ﬁnd any binding sites. Of the identiﬁed
transcription factor binding sites (Supplementary Table 1), CREB is
involved in LDLR expression. The SIRE (sterol-independent regulatory
element), located c.-94 to c.-110 of the promoter, binds CREB in a
cholesterol-independent manner.7 CREB was predicted to bind to the
wild-type sequence, but was abolished in the variant sequence.
Moreover, another predicted transcription factor, OCT1, has been
implicated as being involved in lipoprotein lipase (LPL) expression, and
is critical for hydrolysis of triglycerides in lipoproteins.16,17 Although
OCT1 was predicted to bind by MatInspector and MATCH, there are
no major differences in the scores for the variant and wild-type
binding sites. These algorithms lack the complexity to take account of
physiological conditions. The binding of transcription factors to a
speciﬁc DNA sequence is dependent on various intracellular and
extracellular stimuli within a cell. Therefore, although some transcrip-
tion factors are predicted to bind to these sequences (with scores as
high as 1.0), this does not take into account in vivo conditions such as
chromatin structure, and are hence not ideal representations of what
Figure 1 Illustration of the promoter and 5′UTR region of the LDLR gene. Highlighted boxes illustrate known binding sites. Variants examined in this study
are highlighted in red, and highlighted in yellow is the positive control used. The start sites for transcription are indicated by *. The numbers to the left
indicate the nucleotide number.
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occurs in the cell. Bioinformatics tools should not be used in isolation
but as a guide for experimental research.
The EMSA assay was also inconclusive: one out of the three
functional sites determined by luciferase assay showed no evidence of
binding of a nuclear protein, and this may be because of the protein
requiring a longer binding site than the probe provided or non-
physiological binding conditions. Although we are not aware of any
direct evidence for a role of HIF1A in the control of LDLR expression,
this factor is involved in expression of PCSK9,18 a key gene involved in
cholesterol metabolism, and hence the prediction of its binding here
may be correct.
In order to put the present ﬁndings in context, we have carried out
a systematic review of the published promoter and 5′UTR variants and
examined the functional assay data reported. Including the four
variants examined here, there are 36 variants reported, of which 20
have been directly tested using reporter assays, usually luciferase
(Table 1). Of the four variants identiﬁed after the upstream SREBP1
binding site (which extends from c.-193 to c.-107), two have been
tested and one (c.-217C4T) reported to have higher transcriptional
activity and one (c.-208A4T) with no effect on luciferase activity, and
thus neither are FH causing. The variant tested here at c.-215A4G has
a modest effect on transcription and no EMSA binding was detected.
Figure 2 (a) Measurement of promoter activity using luciferase assay. Fragments containing the wild type and mutant were cloned into the pGL2 promoter,
transfected into Huh7 cells and cultured using DMEM medium. Data were obtained in medium supplemented with 10% bovine calf serum. The mutants
were compared with the wild type, normalised to the value of 1. These results are the average of 8–12 repeats in 3 independent experiments. Error bars
indicate SEM. (b) Measurement of promoter activity using luciferase assay. Data were obtained in medium supplemented with 10% lipid-depleted bovine
calf serum.
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This region contains sequences involved in the Footprint 1 element
responsible for enhancement of LDLR transcription, with the key
nucleotides identiﬁed at c.-218, c.-219 and c.-231,19 but no variants at
these sites have been reported so far. Of the 23 variants between c.-207
and c.-90, where the binding sites for the key transcription factors
SREBP1, SP1 and the TATA box CREBP are located, 14 have been
tested and all found to have a profound effect on luciferase levels.
Excluding the two examined here, the percentage of wild-type activity
reported ranges from 0 to 40% (mean 15%). The modestly lower
~ 50% luciferase noted for the variants tested here (c.-215A4G,
c.-121T4C and c.-101T4C) therefore raises the possibility that these
may not be FH causing, although the data obtained are based on 8–12
replicates and three repeat experiments, and the lower transcriptional
data are statistically robust. To address this, we have used c.-120C4T
as a positive control that has been reported to have only 3% luciferase
activity compared with the wild-type promoter sequence.10 In our
hands, we observe that the variant has 83±9% activity compared with
the wild type, conﬁrming that the variant is FH causing but that the
effect is not so drastic as previously observed. This could be because of
the differences in cell culture conditions; for example, Francova et al10
used the HepG2 cell line compared with the Huh7 hepatoma cells that
we used. However, the reduction in luciferase activity observed with
the novel variants tested here are similar to the reported FH-causing
c.-120C4T variant, strongly supportive of a causal effect of our
variants. Finally, of the eight variants located after the start of
transcription (c.-93 to c.-79), two have been tested and, as with the
c.-13A4G tested here, none have a signiﬁcant effect on promoter
strength.15 Our data suggest that although there is no effect on
luciferase activity for the c.-215G allele, there was a signiﬁcant
reduction in luciferase activity when supplemented in lipid-depleted
conditions. In lipid-depleted conditions, SREBPs activate the
transcription of LDLR by binding to SRE. Therefore, when lipid levels
are low, LDLR expression is increased. However for the c.-215G allele
construct, in lipid-depleted conditions, luciferase expression was
reduced compared with the wild-type construct. Therefore, because
lipid-depleted conditions mimic what occurs in vivo, these data
support the view that this variant is possibly causal of the FH
phenotype, but the status of this variant is still unclear, and
co-segregation analysis in the relatives of this patient may resolve this
issue. The data obtained from this study have been submitted to the
UCL LDLR variant database (https://grenada.lumc.nl/LOVD2/UCL-
Heart/home.php?select_db= LDLR).
There is high cross-species conservation across the whole of the
LDLR promoter region and all the four sites tested here show strong
conservation across six primate and six mammalian species (Table 1).
It is noteworthy that the lowest sequence conservation is seen in sites
in the 5′UTR, where the majority of the tested variants appear not to
affect promoter strength, suggesting that this region does not have a
critical role in control of gene expression. A limitation of the data
reported here is that we do not have any relative samples available
from these probands as the variants were identiﬁed from published
reports,11,12 or from single samples sent to the diagnostic laboratory.
Co-segregation of the variant with elevated lipid levels in relatives
would strengthen the inference that they are FH causing. For all
patients, DNA was tested for the common FH-causing mutations in
the APOB and PCSK9 genes and for the Portuguese patient the entire
PCSK9 gene was screened, but it remains a formal possibility that their
elevated LDL-C levels may be caused by an unidentiﬁed variant in
these genes. Finally, for the EMSAs we did not carry out detailed
competition or supershift experiments to conﬁrm the speciﬁcity or
identity of the nuclear proteins binding to the alleles, as in our
experience these type of experiments are difﬁcult to quantify with
accuracy and often give equivocal results that may not be of direct
relevance to the in vivo situation because the examined element is not
embedded within the full chromatin context.
In vitro luciferase reporter assays for identiﬁed promoter variants
are important in determining the pathogenicity of promoter variants,
allowing diagnostic reporting with greater conﬁdence and subsequent
cascade testing in the relatives of patients with these variations. This
study highlights the difﬁculty of relying solely on in silico methods for
the prediction of the pathogenicity of DNA sequence variants. Ideally,
functional assays should be used to determine effects; however, the
dilemma faced by many diagnostic service laboratories is that such
tests are expensive and time consuming, and the relevant expertise and
resources are rarely available in-house. Therefore, close links with
research groups are key to the transfer of expert knowledge to
diagnostic service laboratories. In conclusion, the functional assays
performed indicate that c.-101T4C and c.-121T4C are likely to be
pathogenic, whereas the c.-13A4G variant appears to be benign and
the status of c.-215A4G remains unclear.
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